Mulder J, De Wolf P, Coutinho RA, Goudsmit J, Lange JM; International Conference on AIDS.
Int Conf AIDS. 1990 Jun 20-23; 6: 198 (abstract no. S.B.449).
Municipal Health Service, Amsterdam, The Netherlands
OBJECTIVE: To study the effects of long term treatment with simplified-dosage zidovudine (+/- acyclovir) of asymptomatic HIV-I infected subjects. METHODS: Eighteen asymptomatic men with persistent p24 antigenemia were treated with zidovudine 250-500 mg 6-hourly for 4-12 weeks and subsequently 500 mg 12-hourly for 188 weeks, of whom 6 in combination with acyclovir 800 mg 6-hourly for 12 weeks and subsequently 1600 mg 12-hourly for 118 weeks. Six additional p24 antigenemic men were treated directly with zidovudine 500 mg 12-hourly for 104 weeks. RESULTS: Disease progression occurred after 60-117 weeks in 6/24 subjects, all to CDC IV-C1. Two of them were treated with zidovudine and acyclovir. In the group of disease progressors median serum p24 levels declined from 539 pg/ml at the start of treatment to 91 pg/ml at the moment AIDS was diagnosed; median CD4+ counts declined from 0.2 to 0.04x10(9)/1. In the group of non-progressors median p24 levels declined from 294 pg/ml at the start of treatment to 97 pg/ml at the end of the study period; median CD4+ counts declined from 0.4 to 0.3x10(9)/1. Two therapy-compliant non-progressors showed both +/- 100% rise in p24 levels. Anaemia caused symptoms in 3 men; prolonged neutropenia did not occur. None developed myopathy. CONCLUSION: Tolerance of zidovudine treatment in asymptomatic subjects is still good after 2-2.5 years. Disease progression occurs despite sustained reduction of serum p24 levels. Combination with acyclovir seems to give no additional benefit.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Acyclovir
- Disease Progression
- HIV-1
- Humans
- Male
- Zidovudine
Other ID:
UI: 102196262
From Meeting Abstracts